CTIS.eu › Cities › Poland › Warsaw
Warsaw
Poland
1,708 total trials
665 recruiting
Filter these 1,708 trials by phase, condition, sponsor and more.
Open in Search →
2023-507064-39-00
5
2024-09-26
generalized Myasthenia Gravis
2023-507803-76-00
10
2024-09-26
Peripheral T-Cell Lymphoma
2023-508811-21-00
10
2024-09-25
Refractory Focal Onset Epilepsy
2024-511688-27-00
4
2024-09-19
Myelofibrosis
2023-507353-15-00
5
2024-09-10
idiopathic pulmonary fibrosis (IPF)
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
2023-506159-12-00
10
2024-09-06
Generalized Myasthenia Gravis
2023-508520-36-00
5
2024-09-06
Seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen
2023-506704-14-00
4
2024-09-04
Moderately to Severely Active Crohn's Disease
2023-507520-23-00
4
2024-09-03
Coronary Artery Disease
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
2023-507692-21-00
3
2024-08-22
Bullous pemphigoid
2022-502757-34-00
1
2024-08-20
Advanced solid tumors
2023-508643-46-00
4
2024-08-02
primary cytomegalovirus (CMV) infection
2023-509096-16-00
6
2024-07-31
Moderately to Severely Active Crohn’s Disease
2023-504910-31-00
5
2024-07-15
Non-small Cell Lung Cancer (NSCLC)
2023-508162-15-00
5
2024-07-12
Chronic HF and comorbid impairment of kidney function who had a recent
2022-502629-16-00
5
2024-07-10
Hemolytic Disease of the Fetus and Newborn (HDFN)
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
2023-507407-59-00
5
2024-07-04
Chronic Obstructive Pulmonary Disease (COPD)
2023-508423-13-00
5
2024-07-01
Chronic lymphocytic leukemia
2022-502570-16-01
4
2024-06-27
Treatment of patients with inadequately controlled moderate to severe
2023-508158-24-00
4
2024-06-25
Moderately to Severely Active Crohn’s Disease
2022-501697-19-01
5
2024-06-18
Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
Showing 625–648 of 1,708 trials